Since Sept. 2019, more and more drug recalls have surfaced regarding heartburn medications containing ranitidine, the most popular of which is Zantac. Once the recalls started, they continued to expand to include nearly all brands of this medication.
Since the recalls of products containing ranitidine began last year, the Food and Drug Administration, along with consumers here in Ohio and elsewhere, pharmaceutical companies and researchers have been asking why N-nitrosodimethylamine was found in unsafe concentrations in the popular heartburn medication. Now, there could finally be some clues as to why the Zantac debacle occurred. Emery Pharma's initial reports may provide promising answers, which could ultimately reveal how to make the medication safe again.
People in Ohio and across the country have become used to hearing about prescription drugs subject to recalls for one reason or another. However, since the recall of the widely popular over-the-counter medication Zantac kicked off several recalls of ranitidine heartburn medications, concern has been raised about other drugs people use every day and can buy at nearly any store. These fears may be well-founded if a state on the west coast has anything to say about it.
Toward the end of 2019, consumers in Ohio and elsewhere learned that a popular medication some have taken for decades contained a human carcinogen that could give them a variety of cancers. Since Sept. 2019, numerous pharmaceutical companies have voluntarily issued recalls for products containing ranitidine, a popular heartburn reliever. Some people may have hoped that the new year would bring better news, but instead, the Food and Drug Administration only continues to widen heartburn drug recalls.
It has been widely publicized across the country fact that N-nitrosodimethylamine (NDMA) could cause cancer in people who take ranitidine products. Up to this point, the Zantac recall has not urged those who take it to stop doing so. That has changed.
People are already beginning to come forward to claim that ranitidine caused their cancer. After taking the medications for decades, they are now receiving diagnoses of a variety of cancers. It is possible that the Zantac recall gave many individuals, including some here in Ohio, the connection they were missing regarding why they ended up with cancer.
Numerous countries decided to simply discontinue the manufacturing, distribution and selling of Zantac and its generic equivalents off the market. Here in the United States, the Food and Drug Administration decided to continue testing and determining how nitrosodimethylamine, popularly known as NDMA, forms in the medication. In the meantime, consumers here in Ohio and elsewhere may be wondering whether they will suffer harm from ranitidine.
Many Ohio residents take dietary supplements for a variety of reasons. Part of the problem with the supplements is that they do not undergo testing necessarily undergo the same scrutiny by the Food and Drug Administration as prescribed medications do, which means they are often classified as unapproved drugs, especially if they contain medications ordinarily prescribed by doctors. The recent recall of a dietary supplement claiming to help with libido occurred because it contained an unapproved drug.
If you are like many other heartburn sufferers here in Ohio, you probably take an over the counter medication for relief. If your medication of choice happens to be Zantac, whose generic version is called Ranitidine, the Food and Drug Administration says you could end up with cancer. According to the FDA, this heartburn medication contains approximately 26,000 times the acceptable level of N-nitrosodimethylamine.
When a recall is announced, people here in Ohio and elsewhere need to understand how dangerous the product in question is. The Food and Drug Administration developed a system to identify the severity of the problem. The most dangerous classification the FDA has is a Class I recall, which means the potential for fatalities is high.